Clearside Biomedical Stock Performance
| CLSD Stock | USD 0.89 0.03 3.49% |
The firm shows a Beta (market volatility) of 0.35, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Clearside Biomedical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Clearside Biomedical is expected to be smaller as well. At this point, Clearside Biomedical has a negative expected return of -0.14%. Please make sure to confirm Clearside Biomedical's jensen alpha, accumulation distribution, relative strength index, as well as the relationship between the value at risk and day typical price , to decide if Clearside Biomedical performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Clearside Biomedical has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
1 | Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye | 12/19/2024 |
2 | Clearside Biomedical Shares Pass Below 50 Day Moving Average - Whats Next - MarketBeat | 12/26/2024 |
3 | Acquisition by Lasezkay George M of 500000 shares of Clearside Biomedical at 0.97 subject to Rule 16b-3 | 01/08/2025 |
4 | Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of ... | 01/22/2025 |
5 | Clearside Biomedical Announces Multiple Medical Meeting Presenta | 01/28/2025 |
6 | Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference | 02/04/2025 |
7 | Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting | 02/10/2025 |
8 | Acquisition by Yerxa Benjamin R of 7813 shares of Clearside Biomedical at 1.31 subject to Rule 16b-3 | 02/14/2025 |
9 | Clearside Biomedicals Asia-Pacific Partner, Arctic Vision, Anno | 02/20/2025 |
10 | Acquisition by Thorp Clay of 15000 shares of Clearside Biomedical at 0.92 subject to Rule 16b-3 | 02/24/2025 |
11 | Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD | 03/06/2025 |
12 | Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 | 03/12/2025 |
| Begin Period Cash Flow | 48.4 M |
Clearside |
Clearside Biomedical Relative Risk vs. Return Landscape
If you would invest 102.00 in Clearside Biomedical on December 17, 2024 and sell it today you would lose (13.00) from holding Clearside Biomedical or give up 12.75% of portfolio value over 90 days. Clearside Biomedical is currently does not generate positive expected returns and assumes 4.2123% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than Clearside, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Clearside Biomedical Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Clearside Biomedical's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Clearside Biomedical, and traders can use it to determine the average amount a Clearside Biomedical's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0336
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CLSD |
Estimated Market Risk
| 4.21 actual daily | 37 63% of assets are more volatile |
Expected Return
| -0.14 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Clearside Biomedical is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Clearside Biomedical by adding Clearside Biomedical to a well-diversified portfolio.
Clearside Biomedical Fundamentals Growth
Clearside Stock prices reflect investors' perceptions of the future prospects and financial health of Clearside Biomedical, and Clearside Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Clearside Stock performance.
| Return On Equity | -13.1 | ||||
| Return On Asset | -0.48 | ||||
| Operating Margin | (5.72) % | ||||
| Current Valuation | 44.68 M | ||||
| Shares Outstanding | 75.84 M | ||||
| Price To Earning | 130.00 X | ||||
| Price To Book | 3.93 X | ||||
| Price To Sales | 8.76 X | ||||
| Revenue | 8.23 M | ||||
| Gross Profit | 7.7 M | ||||
| EBITDA | (23.06 M) | ||||
| Net Income | (32.48 M) | ||||
| Cash And Equivalents | 29.03 M | ||||
| Cash Per Share | 0.48 X | ||||
| Total Debt | 43 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 5.56 X | ||||
| Book Value Per Share | (0.47) X | ||||
| Cash Flow From Operations | (18.14 M) | ||||
| Earnings Per Share | (0.45) X | ||||
| Market Capitalization | 67.48 M | ||||
| Total Asset | 34.02 M | ||||
| Retained Earnings | (320.92 M) | ||||
| Working Capital | 23.31 M | ||||
| Current Asset | 20.48 M | ||||
| Current Liabilities | 5.2 M | ||||
About Clearside Biomedical Performance
By analyzing Clearside Biomedical's fundamental ratios, stakeholders can gain valuable insights into Clearside Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Clearside Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Clearside Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.7 K | 1.5 K | |
| Return On Tangible Assets | (0.86) | (0.90) | |
| Return On Capital Employed | (0.82) | (0.86) | |
| Return On Assets | (0.86) | (0.90) | |
| Return On Equity | 1.84 | 1.93 |
Things to note about Clearside Biomedical performance evaluation
Checking the ongoing alerts about Clearside Biomedical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Clearside Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Clearside Biomedical generated a negative expected return over the last 90 days | |
| Clearside Biomedical has some characteristics of a very speculative penny stock | |
| Clearside Biomedical has high historical volatility and very poor performance | |
| Clearside Biomedical has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 8.23 M. Net Loss for the year was (32.48 M) with profit before overhead, payroll, taxes, and interest of 7.7 M. | |
| Clearside Biomedical currently holds about 29.03 M in cash with (18.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.48. | |
| Clearside Biomedical has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025 |
- Analyzing Clearside Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Clearside Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Clearside Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Clearside Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Clearside Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Clearside Biomedical's stock. These opinions can provide insight into Clearside Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Clearside Stock analysis
When running Clearside Biomedical's price analysis, check to measure Clearside Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearside Biomedical is operating at the current time. Most of Clearside Biomedical's value examination focuses on studying past and present price action to predict the probability of Clearside Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearside Biomedical's price. Additionally, you may evaluate how the addition of Clearside Biomedical to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |